Neratinib in Pakistan (Hernix 40 mg Tablets) – Beacon Pharma

Description

Neratinib (Hernix 40 mg Tablets) – Beacon Pharmaceuticals Ltd.

Price in Pakistan: PKR 446,250 per pack
Pack Size: 180 tablets per pack
Manufacturer: Beacon Pharmaceuticals Ltd.

Neratinib (Hernix 40 mg Tablets):

Hernix (Neratinib 40 mg) by Beacon Pharmaceuticals Ltd. is an advanced oral anticancer medication belonging to the class of tyrosine kinase inhibitors (TKIs).

It is specifically designed to treat HER2-positive breast cancer by targeting and irreversibly blocking the activity of HER2 and other epidermal growth factor receptors (EGFR).

By inhibiting these receptors, Hernix (Neratinib) effectively prevents cancer cell growth and proliferation, making it a key option for patients who have previously completed trastuzumab (Herceptin) therapy and require extended adjuvant treatment to reduce the risk of cancer recurrence.

Beacon Pharmaceuticals ensures international-standard quality and bioequivalence with the original brand Nerlynx® (Puma Biotechnology, USA), offering a reliable and affordable alternative for patients across developing regions.

Therapeutic Uses of Neratinib (Hernix 40 mg Tablets)

Hernix (Neratinib 40 mg) is indicated for:

1. Early-Stage HER2-Positive Breast Cancer:

   • Extended adjuvant therapy for adult patients following trastuzumab-based treatment.

2. Metastatic HER2-Positive Breast Cancer:

   • Used in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have previously received ≥2 anti-HER2 regimens.

Mechanism of Action of Neratinib (Hernix 40 mg Tablets):

Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that targets HER1 (EGFR), HER2, and HER4 receptors. By binding irreversibly to the intracellular domain of these receptors, it blocks signal transduction pathways responsible for cancer cell growth and survival.

This dual inhibition results in prolonged suppression of tumor proliferation and helps prevent disease recurrence in HER2-positive cancers.

Neratinib (Hernix 40 mg Tablets) Dose:

• Recommended Dose: 240 mg once daily (i.e., six tablets of 40 mg) with food.
• Duration: Typically continued for 1 year (in early-stage breast cancer) or as directed by the oncologist.
• Route of Administration: Oral

Antidiarrheal prophylaxis (e.g., loperamide) is usually recommended during the initial weeks of therapy to manage common gastrointestinal side effects.

Common Side Effects of Neratinib (Hernix 40 mg Tablets)

• Diarrhea (most common)
• Nausea, vomiting
• Fatigue
• Abdominal pain
• Rash
• Stomatitis (mouth sores)
• Decreased appetite
• Elevated liver enzymes (transaminases)

Serious adverse effects (rare):

• Severe hepatotoxicity
• Severe or persistent diarrhea leading to dehydration

Precautions

• Avoid use in pregnancy or breastfeeding.
• Monitor liver function tests before and during treatment.
• Caution in patients with a history of gastrointestinal disorders or hepatic impairment.
• Avoid concomitant use with proton pump inhibitors and strong CYP3A4 inhibitors or inducers.

Storage

Store below 30°C in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Disclaimer

This product is a prescription-only medicine and must be used under the supervision of a qualified oncologist or healthcare professional.

Product image may vary from the actual packaging.

Information provided is for educational purposes and not a substitute for professional medical advice.

Summary Table